Earnings call Kuros Biosciences posted FY25 revenue of $146.1M (+72% YoY), adjusted EBITDA of $19.6M (13.4% margin), and first-ever net profit of $2.6M, exceeding guidance. Management guides for at ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果